The FDA has announced plans to take action against GLP-1 receptor agonists it has not approved.[1] The crackdown led telehealth company Hims & Hers to withdraw its new semaglutide compound diet pill (Wegovy) from the market.[1][2] FDA chief Martin Makary said the regulator would take swift action against companies that wholesale illegal copies of drugs and present them as alternatives to approved products.[2] Unapproved products cannot be verified by the FDA for quality, safety, or efficacy, posing a risk to patients.[2] The Hims & Hers pill uses a liposomal formulation of semaglutide, while Novo Nordisk's original Wegovy uses patented SNAC technology.[2] Oral administration via liposomes is problematic, according to analysts, because part of the active substance is broken down in the intestines and does not reach the target effect.[2] Shares of Novo Nordisk stabilized following this FDA action.[2]